ClinicalTrials.gg
TerminatedNCT03347123Updated Feb 28, 2022Results posted

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

A Phase 1/2 interventional study of Epacadostat and Nivolumab in Solid Tumors, sponsored by Incyte Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-28.

Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
A business decision made by Incyte after analysis of data from a sister study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Melanoma by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Melanoma · Incyte Corporation.

Enrollment
17th of 20
11 · median 57
Started
2018
with 3 others
Phase 1/2
11 of 20
none open now
Registered
11th of 20
by date

Among the 20 studies in Melanoma by Incyte Corporation, this one is the 17th largest by enrollment, is one of 4 that started in 2018, is one of 11 in phase 1/2, and was the 11th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 20 studies in Melanoma by Incyte Corporation is open now. The open studies under Melanoma, anywhere →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Melanoma by Incyte Corporation as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.

03

Conditions studied

  • Solid Tumors

Keywords

  • Epacadostat
  • nivolumab
  • ipilimumab
  • lirilumab
  • solid tumor
  • melanoma
  • non-small cell lung cancer (NSCLC)
  • squamous cell carcinoma of the head and neck (SCCHN)
  • IDO inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • During Phase 1, participant with locally advanced or solid tumors with disease progression on or after treatment with available therapies, or who are intolerant to treatment, or who refuse standard treatment.
  • During Phase 2, participant with advanced cancer who have received at least one prior therapy or are treatment naive, depending on the specified tumor type.
  • Presence of per v1.1.
  • (ECOG) performance status of 0 or 1.
  • Expected survival of ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Laboratory and medical history parameters not within the Protocol-defined range.
  • Receipt of anticancer medications or drugs within Protocol-defined time frames.
  • Previous radiotherapy within 7 days of Cycle 1 Day 1.
  • Known active central nervous system and/or carcinomatous meningitis.
  • Prior treatment with any and/or an IDO inhibitor.
  • Active infection requiring systemic therapy.
  • Any active or inactive disease or syndrome
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID

    Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Phase 1: Dose Escalation: Treatment Group A: Cohort 2 Epacadostat 100 mg BID

    Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Phase 1: Dose Escalation: Treatment Group B: Cohort 1 Epacadostat 50 mg BID

    Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Lirilumab

  • Experimental
    Phase 1: Dose Escalation: Treatment Group B: Cohort 2 Epacadostat 100 mg BID

    Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Lirilumab

  • Experimental
    Phase 2: Dose Expansion: Treatment Group A: Cohort A1

    Participants with unresectable or metastatic melanoma (MEL) were planned to be included in this cohort, who did not receive prior systemic therapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Phase 2: Dose Expansion: Treatment Group A: Cohort A2

    Participants with advanced or metastatic non-small cell lung cancer (NSCLC) were planned to be included in this cohort, who have received no more than 1 prior line of platinum-based chemotherapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Phase 2: Dose Expansion: Treatment Group B: Cohort B1

    Participants with recurrent or metastatic serotonin norepinephrine reuptake inhibitor (SCCHN) were planned to be included in this cohort, who received no more than 1 prior line of platinum-based chemotherapy for recurrent or metastatic disease to receive epacadostat in combination with nivolumab and lirilumab at the MTD/PAD determined from dose escalation phase.

    Drug: Epacadostat · Drug: Nivolumab · Drug: Lirilumab

Interventions

  • Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.

    Also known as: INCB024360

  • Nivolumab at the protocol-specified dose and schedule.

    Also known as: Opdivo®, BMS-936558

  • Ipilimumab at the protocol-specified dose and schedule.

    Also known as: Yervoy®, BMS-734016

  • Lirilumab at the protocol-specified dose and schedule.

    Also known as: IPH2102, BMS-986015

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)

    A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.

    Time frame: Screening through up to 100 days after end of treatment, up to approximately 24 months

  2. Phase 2: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

Secondary outcomes

  1. Phase 1: Objective Response Rate (ORR) Based on RECIST v1.1

    ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

  2. Phase 1: Duration of Response (DOR)

    DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

  3. Phase 1: Progression-free Survival (PFS)

    PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

  4. Phase 2: Duration of Response (DOR)

    DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

  5. Phase 2: Progression-free Survival (PFS)

    PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

  6. Phase 2: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    A TEAE was any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.

    Time frame: Screening through up to 100 days for treatment Group A and 150 days for treatment Group B after end of treatment, up to approximately 24 months

07

Results

Posted Feb 28, 2022

Participant flow

Participants took part at 4 study centers in the United States from 21 March 2018 to 29 January 2021.

Participant flow — Overall Study
MilestonePhase 1: Dose Escalataion: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Escalation: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDPhase 1: Dose Escalation: Treatment Group B: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Escalation: Treatment Group B: Cohort 2 Epacadostat 100 mg BIDPhase 2: Dose Expansion: Treatment Group A: Cohort A1Phase 2: Dose Expansion: Treatment Group A: Cohort A2Phase 2: Dose Expansion: Treatment Group B: Cohort B1
Started5600000
Completed0000000
Not completed5600000
Withdrew: Death1200000
Withdrew: Withdrawal by subject1000000
Withdrew: Reason not specified3400000

Outcome measures

PrimaryPhase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)

A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.

Time frame:
Screening through up to 100 days after end of treatment, up to approximately 24 months
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)
percentage of participantsPhase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID
Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)100100
PrimaryPhase 2: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

No measurements were reported for this outcome.

SecondaryPhase 1: Objective Response Rate (ORR) Based on RECIST v1.1

ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

No measurements were reported for this outcome.

SecondaryPhase 1: Duration of Response (DOR)

DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

No measurements were reported for this outcome.

SecondaryPhase 1: Progression-free Survival (PFS)

PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

No measurements were reported for this outcome.

SecondaryPhase 2: Duration of Response (DOR)

DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

No measurements were reported for this outcome.

SecondaryPhase 2: Progression-free Survival (PFS)

PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)

No measurements were reported for this outcome.

SecondaryPhase 2: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

A TEAE was any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.

Time frame:
Screening through up to 100 days for treatment Group A and 150 days for treatment Group B after end of treatment, up to approximately 24 months

No measurements were reported for this outcome.

Adverse events

Collected over Screening through up to 100 days after end of treatment, up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID1/5 (20%)2/5 (40%)5/5 (100%)
Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID2/6 (33.3%)3/6 (50%)6/6 (100%)
Total3/11 (27.3%)5/11 (45.5%)11/11 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPhase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
AnaemiaBlood and lymphatic system disorders1/50/61/11
Atrial fibrillationCardiac disorders1/50/61/11
PolyarthritisMusculoskeletal and connective tissue disorders1/50/61/11
Acute myocardial infarctionCardiac disorders0/51/61/11
DehydrationMetabolism and nutrition disorders0/51/61/11
DiarrhoeaGastrointestinal disorders0/51/61/11
DuodenitisGastrointestinal disorders0/51/61/11
HypokalaemiaMetabolism and nutrition disorders0/51/61/11
HypoxiaRespiratory, thoracic and mediastinal disorders0/51/61/11
Lung infectionInfections and infestations0/51/61/11
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPhase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
DiarrhoeaGastrointestinal disorders3/51/64/11
ArthralgiaMusculoskeletal and connective tissue disorders2/50/62/11
FatigueGeneral disorders2/51/63/11
HypokalaemiaMetabolism and nutrition disorders2/51/63/11
HypothyroidismEndocrine disorders2/52/64/11
Lipase increasedInvestigations2/51/63/11
RashSkin and subcutaneous tissue disorders2/51/63/11
PruritusSkin and subcutaneous tissue disorders1/52/63/11
Pruritus generalisedSkin and subcutaneous tissue disorders1/52/63/11
Urinary tract infectionInfections and infestations1/52/63/11

Baseline characteristics

Full analysis set included all participants enrolled in the study who received at least 1 dose of combination therapy.

Age, Continuous
Age, Continuous(years)Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
Mean65.4 ± 8.7953.8 ± 8.5759.1 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
Female235
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
Hispanic or Latino000
Not Hispanic or Latino358
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5510
More than one race000
Unknown or Not Reported000
Weight
Weight(kilogram (kg))Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
Mean90.464 ± 16.366581.255 ± 26.570285.441 ± 21.9832
Height
Height(centimeter (cm))Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BIDPhase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BIDTotal
Mean173.2 ± 9.20174.2 ± 3.25173.7 ± 6.28
08

Study locations

5 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jan 2021, 34 months.

Results were first posted in Feb 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 20, 2017
StartActual
Mar 21, 2018
Primary completionActual
Jan 29, 2021
CompletionActual
Jan 29, 2021
Results first posted
Feb 28, 2022
Last update
Feb 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03347123
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Mar 21, 2018
Primary completion
Jan 29, 2021
Completion
Jan 29, 2021
Results posted
Feb 28, 2022
Last update
Feb 28, 2022

Study contacts

Medical Monitor Consultant for Incyte
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epacadostat

Start the discussion